0 5 Human human JJ 6 7 T t NN 8 12 cell cell NN 13 23 activation activation NN 24 31 through through IN 32 35 the the DT 36 54 activation-inducer activation-inducer JJ 55 68 molecule/CD69 molecule/cd69 NN 69 77 enhances enhance VBZ 78 81 the the DT 82 90 activity activity NN 91 93 of of IN 94 107 transcription transcription NN 108 114 factor factor NN 115 119 AP-1 ap-1 NN 119 120 . . . 122 125 The the DT 126 135 induction induction NN 136 138 of of IN 139 142 the the DT 143 147 AP-1 ap-1 NN 148 161 transcription transcription NN 162 168 factor factor NN 169 172 has have VBZ 173 177 been be VBN 178 186 ascribed ascribe VBN 187 189 to to TO 190 193 the the DT 194 199 early early JJ 200 206 events event NNS 207 214 leading lead VBG 215 217 to to TO 218 219 T t NN 220 224 cell cell NN 225 240 differentiation differentiation NN 241 244 and and CC 245 255 activation activation NN 255 256 . . . 257 259 We we PRP 260 264 have have VBP 265 272 studied study VBN 273 276 the the DT 277 287 regulation regulation NN 288 290 of of IN 291 295 AP-1 ap-1 NN 296 304 activity activity NN 305 307 in in IN 308 313 human human JJ 314 324 peripheral peripheral JJ 325 330 blood blood NN 331 332 T t NN 333 344 lymphocytes lymphocyte NNS 345 355 stimulated stimulate VBN 356 363 through through IN 364 367 the the DT 368 378 activation activation NN 379 386 inducer inducer NN 387 395 molecule molecule NN 396 397 ( ( ( 397 406 AIM)/CD69 AIM)/CD69 NNP 407 417 activation activation NN 418 425 pathway pathway NN 425 426 . . . 427 434 Phorbol Phorbol NNP 435 441 esters ester NNS 442 445 are be VBP 446 454 required require VBN 455 457 to to TO 458 464 induce induce VB 465 473 AIM/CD69 AIM/CD69 NNP 474 486 cell-surface cell-surface JJ 487 497 expression expression NN 498 500 as as RB 501 505 well well RB 506 508 as as IN 509 512 for for IN 513 523 triggering trigger VBG 524 527 the the DT 528 541 proliferation proliferation NN 542 544 of of IN 545 546 T t NN 547 552 cells cell NNS 553 555 in in IN 556 567 conjunction conjunction NN 568 572 with with IN 573 581 anti-AIM anti-aim JJ 582 585 mAb mab NN 585 586 . . . 587 595 Mobility mobility NN 596 601 shift shift NN 602 608 assays assay NNS 609 615 showed show VBD 616 620 that that IN 621 629 addition addition NN 630 632 of of IN 633 641 anti-AIM anti-aim JJ 642 645 mAb mab NN 646 648 to to TO 649 660 PMA-treated pma-treated JJ 661 662 T t NN 663 674 lymphocytes lymphocyte NNS 675 683 markedly markedly RB 684 692 enhanced enhance VBD 693 696 the the DT 697 704 binding binding NN 705 713 activity activity NN 714 716 of of IN 717 721 AP-1 ap-1 NN 722 724 to to TO 725 728 its its PRP$ 729 736 cognate cognate JJ 737 745 sequence sequence NN 745 746 , , , 747 750 the the DT 751 758 phorbol phorbol NN 759 764 ester ester NN 765 773 response response NN 774 781 element element NN 781 782 . . . 783 785 In in IN 786 794 contrast contrast NN 794 795 , , , 796 804 anti-AIM anti-aim NN 805 808 mAb mab NN 809 812 did do VBD 813 816 not not RB 817 823 induce induce VB 824 827 any any DT 828 834 change change NN 835 837 in in IN 838 841 the the DT 842 849 binding binding NN 850 858 activity activity NN 859 861 of of IN 862 870 NF-kappa NF-kappa NNP 871 872 B B NNP 872 873 , , , 874 875 a a DT 876 889 transcription transcription NN 890 896 factor factor NN 897 902 whose whose WP$ 903 911 activity activity NN 912 914 is be VBZ 915 919 also also RB 920 929 regulated regulate VBN 930 932 by by IN 933 940 protein protein NN 941 947 kinase kinase NNP 948 949 C C NNP 949 950 . . . 951 954 The the DT 955 963 increase increase NN 964 966 in in IN 967 979 AP-1-binding ap-1-binding JJ 980 988 activity activity NN 989 992 was be VBD 993 1004 accompanied accompany VBN 1005 1007 by by IN 1008 1011 the the DT 1012 1018 marked marked JJ 1019 1030 stimulation stimulation NN 1031 1033 of of IN 1034 1037 the the DT 1038 1051 transcription transcription NN 1052 1054 of of IN 1055 1060 c-fos c-fos NN 1061 1064 but but CC 1065 1068 not not RB 1069 1073 that that DT 1074 1076 of of IN 1077 1082 c-jun c-jun NN 1082 1083 . . . 1084 1092 Blockade blockade NN 1093 1095 of of IN 1096 1099 the the DT 1100 1111 DNA-binding dna-binding JJ 1112 1121 complexes complex NNS 1122 1126 with with IN 1127 1129 an an DT 1130 1138 anti-Fos anti-fos JJ 1139 1142 mAb mab NN 1143 1155 demonstrated demonstrate VBD 1156 1157 a a DT 1158 1164 direct direct JJ 1165 1178 participation participation NN 1179 1181 of of IN 1182 1187 c-Fos c-fos NN 1188 1190 in in IN 1191 1194 the the DT 1195 1199 AP-1 ap-1 NN 1200 1209 complexes complex NNS 1210 1217 induced induce VBN 1218 1220 by by IN 1221 1229 anti-AIM anti-aim JJ 1230 1233 mAb mab NN 1233 1234 . . . 1235 1239 Most most JJS 1240 1242 of of IN 1243 1246 the the DT 1247 1251 AP-1 ap-1 NN 1252 1260 activity activity NN 1261 1266 could could MD 1267 1269 be be VB 1270 1280 eliminated eliminate VBN 1281 1285 when when WRB 1286 1289 the the DT 1290 1298 anti-AIM anti-aim NN 1299 1302 mAb mab NN 1303 1306 was be VBD 1307 1312 added add VBN 1313 1315 to to TO 1316 1319 the the DT 1320 1327 culture culture NN 1328 1334 medium medium NN 1335 1337 in in IN 1338 1341 the the DT 1342 1350 presence presence NN 1351 1353 of of IN 1354 1367 cycloheximide cycloheximide NN 1367 1368 , , , 1369 1379 suggesting suggest VBG 1380 1384 that that IN 1385 1387 de de FW 1388 1392 novo novo FW 1393 1400 protein protein NN 1401 1410 synthesis synthesis NN 1411 1413 is be VBZ 1414 1421 crucial crucial JJ 1422 1425 for for IN 1426 1429 the the DT 1430 1439 induction induction NN 1440 1442 of of IN 1443 1455 AP-1-binding ap-1-binding JJ 1456 1464 activity activity NN 1464 1465 . . . 1466 1471 These these DT 1472 1476 data datum NNS 1477 1484 provide provide VBP 1485 1488 the the DT 1489 1497 evidence evidence NN 1498 1502 that that IN 1503 1513 activation activation NN 1514 1516 of of IN 1517 1522 human human JJ 1523 1533 peripheral peripheral JJ 1534 1539 blood blood NN 1540 1541 T t NN 1542 1547 cells cell NNS 1548 1555 through through IN 1556 1559 the the DT 1560 1563 AIM AIM NNP 1564 1574 activation activation NN 1575 1582 pathway pathway NN 1583 1591 regulate regulate VBP 1592 1595 the the DT 1596 1604 activity activity NN 1605 1607 of of IN 1608 1612 AP-1 ap-1 NN 1612 1613 . . . 1614 1623 Therefore therefore RB 1623 1624 , , , 1625 1629 this this DT 1630 1637 pathway pathway NN 1638 1645 appears appear VBZ 1646 1648 as as IN 1649 1650 a a DT 1651 1658 crucial crucial JJ 1659 1663 step step NN 1664 1666 in in IN 1667 1670 the the DT 1671 1681 initiation initiation NN 1682 1684 of of IN 1685 1690 early early JJ 1691 1692 T t NN 1693 1697 cell cell NN 1698 1708 activation activation NN 1709 1715 events event NNS 1715 1716 . . .